Nav: Home

Precision oncology insights revealed for colorectal cancer

March 19, 2019

Next-generation sequencing of tumor DNA from patients with colorectal cancer revealed genetic alterations that were linked to different survival and treatment outcomes in an analysis led by a University of North Carolina Lineberger Comprehensive Cancer Center researcher.

The findings, published in the Journal of Clinical Oncology, could help define strategies to more effectively treat colorectal cancer, the second leading cause of cancer death in the United States.

"This is an example of precision oncology, where using genetics, we are able to stratify tumor types that we once believed were homogeneous, and to identify new patient subgroups that might benefit from tailored therapies," said UNC Lineberger's Federico Innocenti, MD, PhD, associate professor in the UNC Eshelman School of Pharmacy Division of Pharmacotherapy and Experimental Therapeutics.

For the study, researchers analyzed mutations in tumors of 843 patients who participated in a phase III clinical trial. The trial compared treatment with chemotherapy plus either bevacizumab or cetuximab - regimens which are now the standard of care for this disease in the advanced stage. The researchers used tumor samples to analyze genetic mutations in the DNA. Then, they examined associations between the mutations and data on patients' responses to the treatments and survival.

One key finding from the analysis was that patients who had a lot of genetic repeats in their tumor DNA - known as microsatellite instability - had longer survival when treated with bevacizumab compared to patients treated with cetuximab.

"This finding has important potential implications for treatment of patients with microsatellite instability - a subgroup that represented about 7 percent of patients in our study," Innocenti said.

Another key finding was that patients with tumors that had more genetic variation, which they called high tumor mutational burden, lived longer than patients who had tumors with less variation. The level of tumor mutational burden defines a new subgroup of patients with better prognosis, Innocenti reported.

Studies are ongoing in Innocenti's lab to try to understand the role of the body's immune system in contributing to the finding. Researchers want to know if these patients with higher tumor mutational burden will be more responsive to treatments that work by unlocking the immune system against cancer.

"It is crucial to define which patients could be responsive to immunotherapy in this setting, and this study shows the first promising evidence to do so," Innocenti said.

The study also confirmed findings previously made for patients who had mutations in the BRAF gene in their tumors. They found these patients had worse survival compared to patients who didn't. Median survival for patients with the mutation was 13.5 months, compared to 30.6 months in patients without mutations.

"This mutation was a very strong negative prognostic factor," Innocenti said. "There was a clear difference in survival."

There was no difference in the study between the different treatment strategies studied in the trial for patients with or without the BRAF mutation. However, Innocenti said the finding confirms these tumors have a different biology and should be treated differently.

Additional studies are needed to evaluate and confirm findings with therapeutic implications in patients, Innocenti said. Further research is planned to study additional ways of stratifying patients based on their genetic features to improve outcomes.
-end-
In addition to Innocenti, other authors included Fang-Shu Ou, Xueping Qu, Tyler Zemla, Donna Niedzwiecki, Rachel Tam, Shilpi Mahajan, Richard M. Goldberg, Monica M. Bertagnolli, Charles David Blanke, Hanna Sanoff, James Atkins, Blasé Polite, Alan P. Venook, Heinz-Josef Lenz and Omar Kabbarah.

The study was supported by the National Institutes of Health and Genentech.

Conflicts of Interest: None

UNC Lineberger Comprehensive Cancer Center

Related Cancer Articles:

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.
Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.
Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.
Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.
More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.
New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.
American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.
Oncotarget: Cancer pioneer employs physics to approach cancer in last research article
In the cover article of Tuesday's issue of Oncotarget, James Frost, MD, PhD, Kenneth Pienta, MD, and the late Donald Coffey, Ph.D., use a theory of physical and biophysical symmetry to derive a new conceptualization of cancer.
Health indicators for newborns of breast cancer survivors may vary by cancer type
In a study published in the International Journal of Cancer, researchers from the UNC Lineberger Comprehensive Cancer Center analyzed health indicators for children born to young breast cancer survivors in North Carolina.
Few women with history of breast cancer and ovarian cancer take a recommended genetic test
More than 80 percent of women living with a history of breast or ovarian cancer at high-risk of having a gene mutation have never taken the test that can detect it.
More Cancer News and Cancer Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: Reinvention
Change is hard, but it's also an opportunity to discover and reimagine what you thought you knew. From our economy, to music, to even ourselves–this hour TED speakers explore the power of reinvention. Guests include OK Go lead singer Damian Kulash Jr., former college gymnastics coach Valorie Kondos Field, Stockton Mayor Michael Tubbs, and entrepreneur Nick Hanauer.
Now Playing: Science for the People

#562 Superbug to Bedside
By now we're all good and scared about antibiotic resistance, one of the many things coming to get us all. But there's good news, sort of. News antibiotics are coming out! How do they get tested? What does that kind of a trial look like and how does it happen? Host Bethany Brookeshire talks with Matt McCarthy, author of "Superbugs: The Race to Stop an Epidemic", about the ins and outs of testing a new antibiotic in the hospital.
Now Playing: Radiolab

Dispatch 6: Strange Times
Covid has disrupted the most basic routines of our days and nights. But in the middle of a conversation about how to fight the virus, we find a place impervious to the stalled plans and frenetic demands of the outside world. It's a very different kind of front line, where urgent work means moving slow, and time is marked out in tiny pre-planned steps. Then, on a walk through the woods, we consider how the tempo of our lives affects our minds and discover how the beats of biology shape our bodies. This episode was produced with help from Molly Webster and Tracie Hunte. Support Radiolab today at Radiolab.org/donate.